Therapeutic Area | MeSH |
---|---|
infections | D007239 |
skin and connective tissue diseases | D017437 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SIVEXTRO | Cubist Pharmaceuticals | N-205435 RX | 2014-06-20 | 1 products, RLD, RS |
SIVEXTRO | Cubist Pharmaceuticals | N-205436 RX | 2014-06-20 | 1 products, RLD, RS |
Expiration | Code | ||
---|---|---|---|
TEDIZOLID PHOSPHATE, SIVEXTRO, CUBIST PHARMS LLC | |||
2024-06-20 | GAIN | ||
2019-06-20 | NCE |
Code | Description |
---|---|
J3090 | Injection, tedizolid phosphate, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | — | — | — | — | 1 | — | 1 |
Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | 1 | — | 1 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
Endocarditis | D004696 | HP_0100584 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Bacterial infections | D001424 | — | A49 | 3 | — | 3 | — | 1 | 7 |
Infectious skin diseases | D012874 | — | — | — | 1 | 2 | — | 1 | 4 |
Bacterial skin diseases | D017192 | — | — | 1 | 1 | 1 | — | — | 3 |
Pneumonia | D011014 | EFO_0003106 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cellulitis | D002481 | EFO_0003035 | L03.90 | — | 1 | — | — | — | 1 |
Erysipelas | D004886 | — | A46 | — | 1 | — | — | — | 1 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 1 | — | — | — | 1 |
Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 12 | — | — | — | — | 12 |
Gram-positive bacterial infections | D016908 | — | — | 2 | — | — | — | — | 2 |
Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Wound infection | D014946 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Tedizolid phosphate |
INN | tedizolid |
Description | Tedizolid is a member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis. It has a role as an antimicrobial agent, a drug metabolite and a protein synthesis inhibitor. It is a member of pyridines, a member of tetrazoles, an organofluorine compound, an oxazolidinone, a primary alcohol and a carbamate ester. |
Classification | Small molecule |
Drug class | oxazolidinone antibacterials |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](COP(=O)(O)O)OC4=O)cc3F)cn2)n1 |
PDB | — |
CAS-ID | 856867-55-5 |
RxCUI | — |
ChEMBL ID | CHEMBL2105669 |
ChEBI ID | 83326 |
PubChem CID | 11234049 |
DrugBank | DB09042 |
UNII ID | 97HLQ82NGL (ChemIDplus, GSRS) |